Bharat Biotech targets one billion doses of intranasal vaccine annually
Hyderabad: The Hyderabad-based vaccine maker has already approached the Drug Controller General of India (DCGI) for approval to conduct phase-III trials of its intranasal vaccine.
Intranasal vaccine (BBV154) has the potential to prevent!-->…